Clinuvel Pharmaceuticals Limited (FRA:UR9)
Germany
· Delayed Price · Currency is EUR 7.00
+0.23 (3.40%)
At close: Dec 5, 2025
Clinuvel Pharmaceuticals Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Cash & Equivalents | 28.02 | 35.2 | 31.89 | 121.51 | 82.69 | Upgrade
|
| Short-Term Investments | 196.09 | 148.67 | 124.92 | - | - | Upgrade
|
| Cash & Short-Term Investments | 224.11 | 183.87 | 156.81 | 121.51 | 82.69 | Upgrade
|
| Cash Growth | 21.88% | 17.25% | 29.05% | 46.94% | 23.89% | Upgrade
|
| Accounts Receivable | 24.17 | 25.01 | 20.64 | 15.9 | 15.81 | Upgrade
|
| Other Receivables | 3.3 | 1.23 | 1.57 | 0.3 | 0.28 | Upgrade
|
| Receivables | 27.46 | 26.24 | 22.21 | 16.2 | 16.09 | Upgrade
|
| Inventory | 8.82 | 10.63 | 9.52 | 1.83 | 3.19 | Upgrade
|
| Prepaid Expenses | - | - | - | 1.04 | 0.88 | Upgrade
|
| Other Current Assets | 2.58 | 1.33 | 1.07 | - | - | Upgrade
|
| Total Current Assets | 262.97 | 222.06 | 189.62 | 140.58 | 102.85 | Upgrade
|
| Property, Plant & Equipment | 7.13 | 7.72 | 2.85 | 2.7 | 2.6 | Upgrade
|
| Long-Term Investments | 0.21 | 0.13 | - | - | - | Upgrade
|
| Goodwill | - | - | - | 0.19 | 0.19 | Upgrade
|
| Other Intangible Assets | 0.19 | 0.19 | 0.19 | - | - | Upgrade
|
| Long-Term Deferred Tax Assets | 1.26 | 1.02 | 1.06 | 0.48 | 2.93 | Upgrade
|
| Total Assets | 271.75 | 231.12 | 193.71 | 143.95 | 108.57 | Upgrade
|
| Accounts Payable | 2.55 | 2.35 | 2.79 | 0.26 | 4.66 | Upgrade
|
| Accrued Expenses | 2.29 | 1.88 | 1.45 | 2.86 | 3.7 | Upgrade
|
| Current Portion of Leases | 0.43 | 0.37 | 0.3 | 0.32 | 0.26 | Upgrade
|
| Current Income Taxes Payable | 14.55 | 15.85 | 16.09 | 7.28 | 0.1 | Upgrade
|
| Other Current Liabilities | 7.39 | 4.76 | 4.86 | 3.02 | - | Upgrade
|
| Total Current Liabilities | 27.21 | 25.21 | 25.49 | 13.73 | 8.71 | Upgrade
|
| Long-Term Leases | 0.1 | 0.51 | 0.7 | 0.94 | 1.05 | Upgrade
|
| Pension & Post-Retirement Benefits | 0.13 | 0.08 | 0.06 | 0.03 | 0.01 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 3.42 | 2.23 | 2.76 | 3.62 | - | Upgrade
|
| Other Long-Term Liabilities | 0.09 | 0.08 | 0.07 | 0.07 | 0.06 | Upgrade
|
| Total Liabilities | 30.94 | 28.11 | 29.08 | 18.39 | 9.83 | Upgrade
|
| Common Stock | 169.28 | 168.8 | 151.85 | 151.85 | 151.85 | Upgrade
|
| Retained Earnings | 63.63 | 29.96 | -9.77 | -38.4 | -58.13 | Upgrade
|
| Comprehensive Income & Other | 7.9 | 4.25 | 22.56 | 12.11 | 5.02 | Upgrade
|
| Total Common Equity | 240.81 | 203.01 | 164.63 | 125.56 | 98.74 | Upgrade
|
| Shareholders' Equity | 240.81 | 203.01 | 164.63 | 125.56 | 98.74 | Upgrade
|
| Total Liabilities & Equity | 271.75 | 231.12 | 193.71 | 143.95 | 108.57 | Upgrade
|
| Total Debt | 0.53 | 0.88 | 1 | 1.26 | 1.3 | Upgrade
|
| Net Cash (Debt) | 223.58 | 182.99 | 155.81 | 120.25 | 81.39 | Upgrade
|
| Net Cash Growth | 22.18% | 17.44% | 29.57% | 47.75% | 24.39% | Upgrade
|
| Net Cash Per Share | 4.44 | 3.59 | 3.01 | 2.32 | 1.59 | Upgrade
|
| Filing Date Shares Outstanding | 50.12 | 50.08 | 49.41 | 49.41 | 49.41 | Upgrade
|
| Total Common Shares Outstanding | 50.12 | 50.08 | 49.41 | 49.41 | 49.41 | Upgrade
|
| Working Capital | 235.76 | 196.85 | 164.12 | 126.85 | 94.14 | Upgrade
|
| Book Value Per Share | 4.80 | 4.05 | 3.33 | 2.54 | 2.00 | Upgrade
|
| Tangible Book Value | 240.62 | 202.83 | 164.45 | 125.37 | 98.55 | Upgrade
|
| Tangible Book Value Per Share | 4.80 | 4.05 | 3.33 | 2.54 | 1.99 | Upgrade
|
| Land | 5.02 | 4.97 | - | - | - | Upgrade
|
| Machinery | 2.19 | 1.94 | 1.53 | 1.33 | 0.82 | Upgrade
|
| Leasehold Improvements | 1.99 | 1.99 | 1.89 | 1.25 | 1.25 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.